Work

Abstract B070: IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors

Year: 2016

Type: conference-abstract

Source: Cancer Immunology Research

DOI: 10.1158/2326-6066.imm2016-b070

Authors: Anthony Tolcher, David Hong, Ryan Sullivan, James Mier, Geoffrey Shapiro, Joseph Pearlberg, Les Brail, Jahnavi Kharidia, Lixin Han, Claudio Dansky Ullmann, Howard M. Stern, Jedd D. Wolchok

Institutions: South Texas Accelerated Research Therapeutics, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Infinity Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2548884701

Cites:

Cited by: 3

Related to: 10